Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 446

1.

Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.

Ragupathi G, Livingston PO, Hood C, Gathuru J, Krown SE, Chapman PB, Wolchok JD, Williams LJ, Oldfield RC, Hwu WJ.

Clin Cancer Res. 2003 Nov 1;9(14):5214-20.

2.

Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.

Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO.

Int J Cancer. 2000 Mar 1;85(5):659-66.

3.

GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.

Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, Longenecker BM, Yao TJ, Oettgen HF, Livingston PO.

Cancer Res. 1995 Jul 1;55(13):2783-8.

5.

A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.

Ragupathi G, Koide F, Sathyan N, Kagan E, Spassova M, Bornmann W, Gregor P, Reis CA, Clausen H, Danishefsky SJ, Livingston PO.

Cancer Immunol Immunother. 2003 Oct;52(10):608-16. Epub 2003 Jun 17.

PMID:
12811527
6.

Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.

Slovin SF, Ragupathi G, Musselli C, Fernandez C, Diani M, Verbel D, Danishefsky S, Livingston P, Scher HI.

Cancer Immunol Immunother. 2005 Jul;54(7):694-702. Epub 2005 Feb 22.

PMID:
15726361
7.

Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies.

Livingston P, Zhang S, Adluri S, Yao TJ, Graeber L, Ragupathi G, Helling F, Fleisher M.

Cancer Immunol Immunother. 1997 Jan;43(6):324-30.

PMID:
9067403
8.

Ganglioside vaccines with emphasis on GM2.

Livingston P.

Semin Oncol. 1998 Dec;25(6):636-45. Review.

PMID:
9865678
9.

Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.

Krug LM, Ragupathi G, Ng KK, Hood C, Jennings HJ, Guo Z, Kris MG, Miller V, Pizzo B, Tyson L, Baez V, Livingston PO.

Clin Cancer Res. 2004 Feb 1;10(3):916-23.

10.

Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.

Kim SK, Ragupathi G, Cappello S, Kagan E, Livingston PO.

Vaccine. 2000 Oct 15;19(4-5):530-7.

PMID:
11027818
11.

Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.

Sabbatini PJ, Ragupathi G, Hood C, Aghajanian CA, Juretzka M, Iasonos A, Hensley ML, Spassova MK, Ouerfelli O, Spriggs DR, Tew WP, Konner J, Clausen H, Abu Rustum N, Dansihefsky SJ, Livingston PO.

Clin Cancer Res. 2007 Jul 15;13(14):4170-7.

12.

Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.

Ragupathi G, Cappello S, Yi SS, Canter D, Spassova M, Bornmann WG, Danishefsky SJ, Livingston PO.

Vaccine. 2002 Jan 15;20(7-8):1030-8.

PMID:
11803062
13.

Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.

Kitamura K, Livingston PO, Fortunato SR, Stockert E, Helling F, Ritter G, Oettgen HF, Old LJ.

Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2805-9.

14.

Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer.

Dickler MN, Ragupathi G, Liu NX, Musselli C, Martino DJ, Miller VA, Kris MG, Brezicka FT, Livingston PO, Grant SC.

Clin Cancer Res. 1999 Oct;5(10):2773-9.

15.

Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.

Chapman PB, Morrissey DM, Panageas KS, Hamilton WB, Zhan C, Destro AN, Williams L, Israel RJ, Livingston PO.

Clin Cancer Res. 2000 Mar;6(3):874-9.

16.

Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin.

Chapman PB, Morrisey D, Panageas KS, Williams L, Lewis JJ, Israel RJ, Hamilton WB, Livingston PO.

Clin Cancer Res. 2000 Dec;6(12):4658-62.

17.

Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.

Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, Moynahan M, Houghton A, Norton L, Livingston PO.

Clin Cancer Res. 2000 May;6(5):1693-701.

18.

Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci.

Krug LM, Ragupathi G, Hood C, George C, Hong F, Shen R, Abrey L, Jennings HJ, Kris MG, Livingston PO.

Cancer Immunol Immunother. 2012 Jan;61(1):9-18. doi: 10.1007/s00262-011-1083-6. Epub 2011 Aug 3.

19.

Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.

Chapman PB, Wu D, Ragupathi G, Lu S, Williams L, Hwu WJ, Johnson D, Livingston PO.

Clin Cancer Res. 2004 Jul 15;10(14):4717-23.

20.

Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases.

Zhang H, Zhang S, Cheung NK, Ragupathi G, Livingston PO.

Cancer Res. 1998 Jul 1;58(13):2844-9.

Supplemental Content

Support Center